PATENT CLAIM ANALYSIS

Application Number: 15744507
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "130100"]

Abstract:
A novel domain of Aggrus involved in the binding to CLEC-2 was searched for, and monoclonal antibodies recognizing the domain were obtained. The newly found PLAG4 domain is important for Aggrus binding to CLEC-2. Monoclonal antibodies recognizing this region were further developed. The present invention can provide novel Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, cancer metastasis inhibitors, and tumor growth inhibitors using these antibodies.

Claim (Index 15):
A pharmaceutical composition for inhibition of platelet aggregation, inhibition of thrombus formation, inhibition of cancer progression or metastasis, or anti-inflammation, comprising a peptide comprising a region according to  claim 12  as an active ingredient.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 86.0
- Lexical Diversity: 1.53191
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14006498', '14914704', '11912757', '13721547', '13095098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7103716137243377
- 35 USC 102 Novelty (BERT): 0.5503822296403571
- Combined Prediction Score: 0.6943726753159396
- Mean Citation Score: 324.1048380000001
- Max Citation Score: 414.65854
- Similarity Product: 274.7555335154438

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test